Glucocorticoid enhancement of food exposure therapy in Binge Eating Disorder
Phase 3
- Conditions
- F50Eating disorders
- Registration Number
- DRKS00024066
- Lead Sponsor
- niversitätsmedizin Göttingen
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- Pending
- Sex
- All
- Target Recruitment
- 50
Inclusion Criteria
1.18 - 40 years of age
2.Patients must meet DSM-5 (APA, 2013) criteria of BED
3.Willingness and ability to give written informed consent
4.Female subjects of childbearing potential must agree to use acceptable method(s) of contraception for the full study duration.
Exclusion Criteria
1.systemic (i.v. or oral) glucocorticoid treatment within the last 3 months
2.current diagnosis of a psychotic, bipolar, or substance use disorder
3.severe somatic illness (e.g. cancer, cardiovascular disease)
4.current use of psychotropic medication (at baseline)
5.current or planned psychotherapy (during the period of the study)
6.Simultaneous participation in another interventional trial
7.Pregnant or breastfeeding females
Study & Design
- Study Type
- interventional
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method Decrease of food craving in response to real food 3-5 days after treatment
- Secondary Outcome Measures
Name Time Method Decrease in fear of loss of control over eating and arousal/distress in response to real food, food craving in response to visual food cues, amount of food intake, trait level food craving, number of days and episodes of binge eating and overeating 3-5 days after treatment and 1 month after treatment, and continuous decrease in food craving, fear of loss of control over eating and arousal/distress during intervention sessions